38. (new) A vaccine comprising a chimeric non-segmented negative strand RNA virus, the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of said virus and a pharmaceutically acceptable carrier.

39. (new) The vaccine of claim 38 wherein the non-segmented virus is selected from the members of the Paramyxoviridae family.

40. (new) The vaccine of claim 39 wherein the Paramyxoviridae family member is Respiratory Syncytial Virus or parainfluenza.

---

**REMARKS**

According to the Office Action mailed March 11, 2002, claims 1-35 were pending in this application. New claims 36-40 have been added to more distinctly point out and claim what Applicants consider as the invention. The new claims 36-40 are fully supported by the instant specification, see, *e.g.*, the table below, and do not represent new subject matter. Claims 1-40, therefore, will be pending upon entry of the present amendments.

| CLAIMS | SUPPORT IN SPECIFICATION |
|---|---|
| 36 | page 15, lines 27-28 |
| 37 | section 8.1; page 51, line 10 to page 53, line 5 |
| 38-40 | page 2, lines 14-23; page 14, lines 1-8; page 22, lines 22-25; and page 30, lines 13-21 |

The Examiner has required restriction of the claims under 35 U.S.C. § 121 to one of the following inventions:

I. Claims 1-12, drawn to isolated respiratory syncytial virus (RSV) with a M2-2, SH, NS1, or NS2 gene mutation classified in class 435, subclass 236.

II. Claim 13, drawn to isolated RSV with a M2-1 gene mutation, classified in class 435, subclass 236.